Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amantadine extended release - Adamas Pharmaceuticals

Next Previous
Search
Drug Profile

Amantadine extended release - Adamas Pharmaceuticals

Alternative Names: ADS-5101; ADS-5102; Amantadine controlled release; Amantadine ER; Amantadine HCl; Amantadine HCl extended release; GOCOVRI; GOCOVRI extended release; Nurelin

Latest Information Update: 18 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adamas Pharmaceuticals
  • Class Adamantanes; Antiparkinsonians; Antivirals; Organic bridged compounds; Small molecules
  • Mechanism of Action Dopamine receptor agonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug-induced dyskinesia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Drug-induced dyskinesia
  • Discontinued Brain injuries; Movement disorders

Most Recent Events

  • 18 Mar 2024 Adamas Pharmaceuticals has a patent pending for Amantadine extended release globally and holds patent protection for it in the USA and other regions
  • 02 Apr 2022 Pooled efficacy and safety results from phase III trials in Drug-induced dyskinesia presented at the 74th Annual Meeting of the American Academy of Neurology (AAN-2022)
  • 24 Nov 2021 Adamas Pharmaceuticals has been acquired by Supernus Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top